Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Obesity matters for drug developers
Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%. The R&D pipeline is filling up as more and more companies try to grab a slice of this…
Report library
EvaluatePharma World Preview 2019, Outlook to 2024
Worldwide prescription drugs sales predicted to reach $1.18trn in 2024, with a compound annual growth of 6.9%, significantly higher than the 1.7% CAGR between…
EvaluatePharma Orphan Drug Report 2019
$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…
Vantage Pharma, Biotech and Medtech 2018 in Review
Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for…
Vantage 2019 Preview
2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…
First-line lung cancer: can Keytruda be stopped?
Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC. 2018 started with the promise of a first-line lung…
EvaluateMedTech World Preview 2018, Outlook to 2024
Report Highlights Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players Neurology set to be the…
Vantage Pharma, Biotech & Medtech Half-Year Review 2018
Report Highlights Big biotech and big pharma stocks were largely shunned by investors over the first half of the year Demand for new biotech issues shows no sign of…
EvaluatePharma World Preview 2018, Outlook to 2024
Report Highlights Worldwide prescription drug sales accelerate to $1.2 trillion by 2024, as unmet need drives annual compound growth to over 6% R&D spend is…
ASCO: Skirmishes Break Out In The Great Lung Cancer Battle
Report Highlights For prescribers, at least, it is becoming ever more important to stay up to date with the numerous subgroups into which first-line NSCLC is being…
EP Vantage Pharma, Biotech and Medtech 2017 In Review
Report Highlights All major healthcare indices climbed in 2017, echoing wider stock market strength The $80bn spent on pharma & biotech acquisitions in 2017 makes…
